September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
20 citations
,
September 2005 in “Endocrinology” Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
May 2024 in “International journal of medicine and psychology.” Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
February 2025 in “Iranian journal of pharmaceutical research”
1 citations
,
March 2011 in “Informa Healthcare eBooks” Isotretinoin is a preferred treatment for severe acne, often leading to long-term improvement, but requires careful monitoring due to potential side effects.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
May 1981 in “Inpharma (Balgowlah)” Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.
October 2022 in “The Journal of Clinical Pharmacology” Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
21 citations
,
February 2021 in “BMJ case reports” Anabolic steroid users may face higher risk of severe COVID-19.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
1 citations
,
January 2010 in “SRX Pharmacology” Bupropion SR may help treat trichotillomania.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.